Industry reports
Editor highlights

Free Market Research Guides to Download

Pathology Analysis & Statistics, April 2014

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

1-30 of 51 reports
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

  • $ 3 500
  • Industry report
  • March 2014
  • by GBI Research

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool Summary GBI Research, the leading business intelligence ...

  • Industries : Pathology
  • Countries : World
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

  • $ 3 500
  • Industry report
  • February 2014
  • by GBI Research

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth Summary GBI Research, a leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • $ 3 500
  • Industry report
  • January 2014
  • by GBI Research

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape Summary GBI Research, has released the ...

  • Industries : Pathology
  • Countries : World
Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

  • $ 3 500
  • Industry report
  • December 2013
  • by GBI Research

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation Summary The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, ...

  • Industries : Pathology
  • Countries : World
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

  • $ 3 500
  • Industry report
  • December 2013
  • by GBI Research

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Summary GBI Research has released the pharma ...

  • Industries : Pathology
  • Countries : World
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

  • $ 3 500
  • Industry report
  • December 2013
  • by GBI Research

Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth Summary GBI Research, has released the pharma ...

  • Industries : Pathology
  • Countries : World, Japan, United States, Europe, Canada
Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

  • $ 3 500
  • Industry report
  • November 2013
  • by GBI Research

Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use Summary GBI Research has released its pharmaceutical ...

  • Industries : Pathology
  • Countries : World, Australia, India, Japan, China, Asia
Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat

Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat

  • $ 3 500
  • Industry report
  • November 2013
  • by GBI Research

Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat Summary GBI Research has released its pharmaceutical ...

  • Industries : Pathology
  • Countries : World
Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

  • $ 3 500
  • Industry report
  • October 2013
  • by GBI Research

Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation Summary GBI Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis ...

  • Industries : Pathology
  • Countries : World
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

  • $ 3 500
  • Industry report
  • September 2013
  • by GBI Research

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World, Australia, China, Japan, India, Asia
Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

  • $ 3 500
  • Industry report
  • July 2013
  • by GBI Research

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease

  • $ 3 500
  • Industry report
  • May 2013
  • by GBI Research

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease Summary ...

  • Industries : Pathology
  • Countries : Australia, Japan, United States, India, World, Europe, China
Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff

Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff

  • $ 3 500
  • Industry report
  • March 2013
  • by GBI Research

Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World, Italy, Germany, Japan, Spain, France, United States, United Kingdom, Europe
Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

  • $ 3 500
  • Industry report
  • January 2013
  • by GBI Research

Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential Summary GBI Research has released its latest research, ?Acquired ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need

Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need

  • $ 3 500
  • Industry report
  • January 2013
  • by GBI Research

Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, Europe, United States, United Kingdom
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs% Major Market Share

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs% Major Market Share

  • $ 3 500
  • Company report
  • November 2012
  • by GBI Research

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share Summary GBI Research, the leading business intelligence provider, has released its latest ...

  • Industries : Pathology
  • Countries : World
Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

  • $ 3 500
  • Industry report
  • September 2012
  • by GBI Research

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans Summary GBI Research, the leading business intelligence provider has released its latest ...

  • Industries : Pathology
  • Countries : United States
Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise

Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise

  • $ 3 500
  • Industry report
  • July 2012
  • by GBI Research

Summary GBI Research, the leading business intelligence provider, has released its latest research, ?Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cance ...

  • Industries : Pathology
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

  • $ 3 500
  • Industry report
  • May 2012
  • by GBI Research

Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

  • $ 3 500
  • Industry report
  • April 2012
  • by GBI Research

Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies

Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies

  • $ 3 500
  • Industry report
  • April 2012
  • by GBI Research

Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies Summary GBI Research's report "Herpes Market to 2018 - Genericization Compels ...

  • Industries : Pathology
  • Countries : World
Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

  • $ 3 500
  • Industry report
  • March 2012
  • by GBI Research

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future Summary GBI Research's new report, ?Urological Disorders Therapeutics ...

  • Industries : Pathology
  • Countries : World
Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies

Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies

  • $ 3 500
  • Industry report
  • March 2012
  • by GBI Research

Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies Summary GBI Research has released its latest research, ...

  • Industries : Pathology
  • Countries : World
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

  • $ 3 500
  • Industry report
  • February 2012
  • by GBI Research

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules Summary GBI Research, ...

  • Industries : Pathology
  • Countries : World
ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance Summary GBI Research, the leading business intelligence provider, has ...

  • Industries : Pathology
  • Countries : World
Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma Summary GBI Research, the leading business intelligence provider, has released its latest ...

  • Industries : Pathology
  • Countries : World
Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

  • $ 3 500
  • Industry report
  • December 2011
  • by GBI Research

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World
Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

  • $ 3 500
  • Industry report
  • November 2011
  • by GBI Research

Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD Summary GBI Research's report, ?Clinical Trial Recruitment in Respiratory Diseases - Most Clinical ...

  • Industries : Pathology
  • Countries : Brazil, India, China, World
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

  • $ 3 500
  • Industry report
  • November 2011
  • by GBI Research

Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology Summary GBI Research, the leading business intelligence provider, has released ...

  • Industries : Pathology
  • Countries : Japan, World, United States, Europe

» View Public Reports

About 12 000 reports

The Australian Pharmaceutical Business Brief

  • Industry report
  • April 2014
  • 8 pages
  • by Corporation

... To compare the expenditure of other chronic diseases, particularly chronic diseases that share many of the same risk factors such as ckd [14]. As a result, this investigation will determine and compare ...

U.s. Diabete Sector

April 2014

» Read our Company Profiles

2 Companies

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.